Eli Lilly's Director, Lilly Endowment Inc, sold a total of 15,485 shares of common stock on February 20, 2025, in multiple transactions with prices ranging from $877 to $880.19. Such sales by key executives or major shareholders often indicate that the company's stock may be overvalued. Investors should remain cautious.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.